MedPageToday
MedPage Today) — As CAR T-cell therapy has become a transformative option in multiple myeloma, a first-of-its-kind trial now extends that potential to relapsed/refractory light chain (AL) amyloidosis. At the recent American Society of Clinical…
Read More
BCMA CAR-T Yields 100% Response Rate in Small AL Amyloidosis Trial
Buffy Grumbles
23:25
MedPage Today) — As CAR T-cell therapy has become a transformative option in multiple myeloma, a first-of-its-kind trial now extends that potential to relapsed/refractory light chain (AL) amyloidosis. At the recent American Society of Clinical…
